4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease

Cardiovascular disorders in aging adults rarely occur in isolation. The clinical triad of Heart Failure (HF), Atrial Fibrillation (AFib), and Peripheral Vascular Disease (PVD/PAD) represents a complex web of neurohormonal activation, hemodynamic stress, and vascular calcification. Heart failure affects over 6.5 million Americans, AFib increases ischemic stroke risk fivefold, and lower extremity peripheral artery disease serves as a potent harbinger of systemic cardiovascular mortality.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands mastery of the 2022 AHA/ACC/HFSA Heart Failure Guidelines, the four foundational pillars of Guideline-Directed Medical Therapy (GDMT), $\text{CHA}_2\text{DS}_2\text{-VASc}$ anticoagulation protocols, and the non-invasive vascular evaluation of claudication and limb ulcerations.

---

1. Heart Failure Classification & The Staging Continuum

The 2022 AHA/ACC/HFSA guidelines classify heart failure according to Left Ventricular Ejection Fraction (LVEF) measured by echocardiography, alongside a 4-stage disease progression model.

+-----------------------------------------------------------------------------+
|                   HEART FAILURE CLASSIFICATION BY EJECTION FRACTION         |
|                                                                             |
|   PHENOTYPE                     LVEF CRITERIA      PATHOPHYSIOLOGICAL FOCUS |
|   -----------------------------------------------------------------------   |
|   HFrEF (Reduced EF)            <= 40%             Systolic pump failure,   |
|                                                    eccentric remodeling     |
|   HFmrEF (Mildly Reduced EF)    41% to 49%         Intermediate phenotype,  |
|                                                    benefits from HFrEF GDMT |
|   HFpEF (Preserved EF)          >= 50%             Diastolic relaxation     |
|                                                    failure, high filling    |
|                                                    pressures, stiff LV      |
|   HFimpEF (Improved EF)         Baseline <= 40%,   Recovered systolic       |
|                                 >= 10-point rise,  function; MUST CONTINUE  |
|                                 second LVEF > 40%  GDMT indefinitely!       |
+-----------------------------------------------------------------------------+

AHA/ACC Stages of Heart Failure vs. NYHA Functional Classes

+-----------------------------------------------------------------------------+
|               AHA/ACC STAGES VS. NYHA FUNCTIONAL CLASSIFICATION             |
|                                                                             |
|   ACC/AHA STAGES (Progression of Disease - CANNOT MOVE BACKWARD):           |
|   * STAGE A: At Risk for HF (HTN, DM, ASCVD, obesity, family history;       |
|              no structural disease or symptoms).                            |
|   * STAGE B: Pre-Heart Failure (Structural heart disease, LVH, reduced LVEF,|
|              or elevated BNP/cTn; NO prior or current symptoms).            |
|   * STAGE C: Symptomatic Heart Failure (Structural disease WITH current or   |
|              prior symptoms of heart failure).                              |
|   * STAGE D: Advanced Heart Failure (Refractory end-stage symptoms at rest   |
|              interfering with daily life despite maximal GDMT).             |
|                                                                             |
|   NYHA FUNCTIONAL CLASSES (Functional Capacity - FLUCTUATES OVER TIME):     |
|   * CLASS I:   No limitation of physical activity. Ordinary activity        |
|                does not cause undue fatigue, palpitation, or dyspnea.       |
|   * CLASS II:  Slight limitation of physical activity. Comfortable at rest; |
|                ordinary physical activity results in symptoms.              |
|   * CLASS III: Marked limitation of physical activity. Comfortable at rest; |
|                less than ordinary activity causes fatigue or dyspnea.       |
|   * CLASS IV:  Unable to carry on any physical activity without discomfort. |
|                Symptoms of heart failure present AT REST.                   |
+-----------------------------------------------------------------------------+

---

2. Diagnostic Workup & Biomarker Kinetics: BNP vs. NT-proBNP

When evaluating acute or chronic dyspnea, circulating natriuretic peptides provide vital diagnostic and prognostic information.

+-----------------------------------------------------------------------------+
|                 NATRIURETIC PEPTIDE SYNTHESIS & CLEAVAGE                    |
|                                                                             |
|                 [VENTRICULAR MYOCYTE MYOCARDIAL WALL STRETCH]               |
|                                    |                                        |
|                                    v                                        |
|                         [PRO-BNP (108 Amino Acids)]                         |
|                                    | (Cleaved by Furin / Corin)             |
|                   +----------------+----------------+                       |
|                   |                                 |                       |
|                   v                                 v                       |
|         [BNP (Active Hormone)]          [NT-proBNP (Inactive Fragment)]     |
|         - 32 Amino Acids                - 76 Amino Acids                    |
|         - Half-life: 20 minutes         - Half-life: 70-120 minutes         |
|         - Cleared by: NEPRILYSIN &      - Cleared by: RENAL FILTRATION      |
|           NPR-C clearance receptors       (Sensitive to kidney dysfunction) |
+-----------------------------------------------------------------------------+

Clinical Biomarker Nuances & The ARNI Effect:

• Diagnostic Cutoffs for Acute Dyspnea Exclusion:
  • BNP $<100\text{ pg/mL}$ or NT-proBNP $<300\text{ pg/mL}$ has a $\ge 98%$ negative predictive value to rule out heart failure.
  • Age-stratified NT-proBNP rule-in thresholds for acute HF: Age $<50$ ($>450\text{ pg/mL}$); Age 50–75 ($>900\text{ pg/mL}$); Age $>75$ ($>1,800\text{ pg/mL}$).
• The ARNI (Sacubitril) Biomarker Trap:
  • Sacubitril is a neprilysin inhibitor. Because neprilysin is the primary enzyme responsible for degrading biologically active BNP, patients on sacubitril/valsartan will exhibit paradoxically elevated BNP levels that do not reflect worsening heart failure.
  • In contrast, NT-proBNP is NOT a substrate for neprilysin (it is cleared solely by the kidneys). Therefore, in patients taking an ARNI, NT-proBNP must be used exclusively to assess disease severity and monitor clinical decompensation.
• Obesity Effect: Patients with a $\text{BMI} \ge 30\text{ kg/m}^2$ have significantly lower circulating baseline BNP/NT-proBNP levels (~50% lower) due to increased adipose clearance receptor expression.

---

3. Guideline-Directed Medical Therapy (GDMT) for HFrEF: The Four Foundational Pillars

The 2022 AHA/ACC/HFSA guidelines establish that all patients with HFrEF (LVEF $\le 40%$) should be initiated on The Four Foundational Pillars of GDMT simultaneously or in rapid succession, as this combination reduces all-cause mortality by over 73% compared to placebo.

+-----------------------------------------------------------------------------+
|                   THE FOUR FOUNDATIONAL PILLARS OF HFrEF GDMT               |
|                                                                             |
|   [PILLAR 1: ARNI (OR ACEi / ARB)]                                          |
|   * Sacubitril/Valsartan (24/26 mg to 97/103 mg BID) - PREFERRED FIRST-LINE |
|   * PARADIGM-HF: 20% reduction in CV death / HF hospitalization vs enalapril|
|   * MANDATORY: 36-hour washout when switching from ACE inhibitor!           |
|                                                                             |
|   [PILLAR 2: EVIDENCE-BASED BETA-BLOCKER]                                   |
|   * Specifically: Carvedilol, Metoprolol Succinate ER, or Bisoprolol        |
|   * Must be clinically euvolemic before initiation; start low, titrate slow |
|   * Note: Atenolol, Metoprolol Tartrate do NOT reduce HFrEF mortality!      |
|                                                                             |
|   [PILLAR 3: MINERALOCORTICOID RECEPTOR ANTAGONIST (MRA)]                   |
|   * Spironolactone (12.5-25 mg daily) or Eplerenone (25-50 mg daily)        |
|   * RALES / EMPHASIS-HF: 30% mortality reduction; slows cardiac fibrosis    |
|   * Criteria: Serum K+ < 5.0 mEq/L and eGFR >= 30 mL/min                    |
|                                                                             |
|   [PILLAR 4: SGLT2 INHIBITOR]                                               |
|   * Dapagliflozin (10 mg daily) or Empagliflozin (10 mg daily)              |
|   * DAPA-HF / EMPEROR-Reduced: Reduces CV death / HF hospitalization        |
|   * Effective in BOTH diabetic and non-diabetic patients; eGFR >= 20-25     |
+-----------------------------------------------------------------------------+

Comprehensive GDMT Pharmacotherapy & Safety Matrix

---

4. Evidence-Based Management of HFpEF & HFmrEF

Heart Failure with Preserved Ejection Fraction (HFpEF, $\text{LVEF} \ge 50%$) represents over half of all heart failure cases in patients $>65$ years, driven by obesity, hypertension, arterial stiffness, and diabetic microvascular inflammation.

• SGLT2 Inhibitors (Class 1 Recommendation): The milestone EMPEROR-Preserved (empagliflozin) and DELIVER (dapagliflozin) trials demonstrated significant reductions in cardiovascular death and HF hospitalizations in HFpEF and HFmrEF, establishing SGLT2 inhibitors as the first foundational therapy for preserved ejection fraction.
• Loop Diuretics: Titrated to manage pulmonary congestion and peripheral edema.
• MRAs (Spironolactone): Class 2b recommendation (TOPCAT trial demonstrated reduced hospitalizations, especially in patients with LVEF at the lower end of the preserved spectrum: 45–57%).
• ARNI (Sacubitril/Valsartan): Class 2b recommendation (PARAGON-HF trial showed benefits in hospitalizations in patients with lower LVEF and females).
• Blood Pressure & Atrial Fibrillation Control: Target $\text{SBP} < 130\text{ mmHg}$; rapid AFib shortens diastolic filling time, precipitating acute pulmonary edema in stiff ventricles.

---

5. Atrial Fibrillation: Presentation, Rate vs. Rhythm & Instability

Atrial Fibrillation (AFib) is a supraventricular tachyarrhythmia characterized by uncoordinated atrial activation and chaotic, irregular ventricular response.

+-----------------------------------------------------------------------------+
|                        ATRIAL FIBRILLATION 12-LEAD ECG                      |
|                                                                             |
|   1. "IRREGULARLY IRREGULAR" R-R intervals (no repeating pattern)           |
|   2. ABSENCE OF DISCRETE P WAVES (replaced by fibrillatory 'f' waves: 350-600/min)|
|   3. Narrow QRS complexes (unless bundle branch block or aberrancy present) |
+-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+
|                   ATRIAL FIBRILLATION MANAGEMENT ALGORITHM                  |
|                                                                             |
|                      [PATIENT IN ATRIAL FIBRILLATION]                       |
|                                    |                                        |
|         +--------------------------+--------------------------+             |
|         |                                                     |             |
|         v                                                     v             |
|   [HEMODYNAMICALLY UNSTABLE]                           [HEMODYNAMICALLY STABLE]|
|   - Sustained hypotension / shock                      - Rate vs Rhythm     |
|   - Acute altered mental status                        - Assess stroke risk |
|   - Refractory ischemic chest pain                     - Anticoagulation    |
|   - Acute flash pulmonary edema                               |             |
|         |                                                     v             |
|         v                                             [RATE CONTROL]        |
|   [IMMEDIATE SYNCHRONIZED                             - Beta-Blocker OR     |
|    DIRECT-CURRENT CARDIOVERSION (DCCV)]               - Non-DHP CCB         |
|                                                       - Goal HR < 80 (rest) |
+-----------------------------------------------------------------------------+

Clinical Management Strategies:

• Rate Control (First-Line in Most Older Adults):
  • Beta-Blockers: Metoprolol, Atenolol, Carvedilol (preferred in CAD or HFrEF).
  • Non-Dihydropyridine CCBs: Diltiazem or Verapamil (Strictly avoid in HFrEF / LVEF ≤40% due to negative inotropic depression).
  • Digoxin: Useful adjunct in sedentary elders or co-existing HFrEF; narrow therapeutic window ($0.5–0.9\text{ ng/mL}$).
  • Target Heart Rate: Resting HR $<80\text{ bpm}$ (symptomatic) or $<110\text{ bpm}$ (lenient rate control per RACE II trial if asymptomatic and LV function preserved).
• Rhythm Control (Restoration of Sinus Rhythm): Preferred in younger patients, highly symptomatic individuals, heart failure triggered by AFib (tachycardia-induced cardiomyopathy), or failure of rate control. Modalities: Antiarrhythmic drugs (Amiodarone, Dofetilide, Flecainide [avoid flecainide in structural/ischemic heart disease]), synchronized cardioversion, and Catheter Pulmonary Vein Isolation (PVI) Ablation.

---

6. Stroke Risk Stratification: CHA2DS2-VASc & Anticoagulation Protocols

Ischemic stroke in AFib results from blood stasis in the Left Atrial Appendage (LAA) leading to thrombus formation and cerebral embolization.

+-----------------------------------------------------------------------------+
|                    CHA2DS2-VASc STROKE RISK SCORING SYSTEM                  |
|                                                                             |
|   RISK FACTOR                                                 POINTS ASSIGNED|
|   -----------------------------------------------------------------------   |
|   C - Congestive Heart Failure (or LVEF <= 40%)               1             |
|   H - Hypertension (or on antihypertensive therapy)           1             |
|   A2- Age >= 75 years                                         2             |
|   D - Diabetes Mellitus                                       1             |
|   S2- Prior Stroke, TIA, or Thromboembolism                   2             |
|   V - Vascular Disease (Prior MI, PAD, or Aortic Plaque)      1             |
|   A - Age 65 to 74 years                                      1             |
|   Sc- Sex Category: Female                                    1             |
|   -----------------------------------------------------------------------   |
|   MAXIMUM POSSIBLE SCORE:                                     9             |
+-----------------------------------------------------------------------------+

Anticoagulation Decision Matrix & DOAC Dosing:

+-----------------------------------------------------------------------------+
|                   ANTICOAGULATION THRESHOLDS IN NON-VALVULAR AFIB           |
|                                                                             |
|   MEN: SCORE >= 2   |   WOMEN: SCORE >= 3  ---> ORAL ANTICOAGULATION (OAC)  |
|                                                 STRONGLY RECOMMENDED (CLASS 1)|
|                                                                             |
|   MEN: SCORE = 1    |   WOMEN: SCORE = 2   ---> OAC MAY BE CONSIDERED       |
|                                                 (CLASS 2b)                  |
|                                                                             |
|   MEN: SCORE = 0    |   WOMEN: SCORE = 1   ---> NO ANTITHROMBOTIC THERAPY    |
|                                                 (Omit Aspirin and OAC)      |
+-----------------------------------------------------------------------------+

DOACs vs. Warfarin Comparison Table

[!NOTE] Aspirin Obsolete for AFib Stroke Prevention: Antiplatelet monotherapy (Aspirin) or dual antiplatelet therapy (Aspirin + Clopidogrel) is no longer recommended for stroke prevention in atrial fibrillation. Clinical trials have demonstrated that aspirin provides negligible stroke protection in AFib while incurring major bleeding rates comparable to oral anticoagulants.

---

7. Peripheral Artery Disease (PAD): ABI & Claudication Management

Lower extremity Peripheral Artery Disease (PAD) is an atherosclerotic disorder causing arterial luminal stenosis, impairing distal skeletal muscle perfusion during ambulation.

+-----------------------------------------------------------------------------+
|                        ANKLE-BRACHIAL INDEX (ABI) FORMULA                   |
|                                                                             |
|             \text{ABI} = \frac{\text{Highest Systolic Pressure in Ankle}}{\text{Highest Systolic Pressure in Both Arms}}|
|                                                                             |
|   - Measure with handheld continuous-wave Doppler and blood pressure cuff   |
|   - Ankle pressure: take higher of Posterior Tibial (PT) or Dorsalis Pedis  |
+-----------------------------------------------------------------------------+

+-----------------------------------------------------------------------------+
|                          ABI CLINICAL INTERPRETATION                        |
|                                                                             |
|   ABI VALUE              CLINICAL DIAGNOSIS & STAGING                       |
|   -----------------------------------------------------------------------   |
|   1.00 - 1.40            NORMAL ARTERIAL PERFUSION                          |
|   0.91 - 0.99            BORDERLINE PERFUSION (Consider post-exercise ABI)  |
|   <= 0.90                DIAGNOSTIC OF PERIPHERAL ARTERY DISEASE (PAD)      |
|     0.71 - 0.90          - Mild Arterial Obstruction (Claudication)         |
|     0.41 - 0.70          - Moderate Obstruction (Severe Claudication)       |
|     <= 0.40              - Severe Obstruction / Critical Limb Ischemia      |
|   > 1.40                 NON-COMPRESSIBLE / CALCIFIED ARTERIES              |
|                          (Medial sclerosis in DM/ESRD; order TOE-BRACHIAL   |
|                          INDEX [TBI]; abnormal if TBI <= 0.70)              |
+-----------------------------------------------------------------------------+

Comprehensive Management of PAD:

1. Systemic ASCVD Risk Modification (Mandatory):
   • High-Intensity Statin: Atorvastatin 80 mg or Rosuvastatin 40 mg daily.
   • Antiplatelet Monotherapy: Aspirin 81 mg daily OR Clopidogrel 75 mg daily (CAPRIE trial demonstrated slight superiority of clopidogrel in PAD).
   • Dual Pathway Inhibition (COMPASS Protocol): Low-dose Rivaroxaban 2.5 mg BID plus Aspirin 81 mg daily reduces major adverse limb events (amputation) and MACE in high-risk PAD.
   • Smoking Cessation: The single most critical modifiable factor to halt disease progression.
2. Symptomatic Claudication Interventions:
   • Supervised Exercise Therapy (SET): First-line therapy (Class 1). 30–45 minutes of treadmill walking 3–5 times per week for at least 12 weeks. Patient walks to moderate-to-severe claudication pain, rests until pain resolves, then resumes walking. Increases pain-free walking distance by 150–200%.
   • Cilostazol (100 mg orally BID): Phosphodiesterase-3 (PDE-3) inhibitor; promotes arterial vasodilation and inhibits platelet aggregation. Increases maximum walking distance.

     [!WARNING] Black Box Warning for Cilostazol: Cilostazol is strictly contraindicated in patients with heart failure of any severity (NYHA Class I–IV or reduced LVEF). PDE-3 inhibitors possess inotropic properties that increase ventricular arrhythmias and mortality in heart failure patients.

---

8. Chronic Venous Insufficiency (CVI) & Vascular Ulcer Differential

Chronic Venous Insufficiency (CVI) results from incompetent venous valves and venous hypertension, leading to lower extremity venous pooling, capillary leak, and skin breakdown.

+-----------------------------------------------------------------------------+
|                 ARTERIAL VS. VENOUS LOWER EXTREMITY ULCERS                  |
|                                                                             |
|   FEATURE               ARTERIAL INSUFFICIENCY       VENOUS INSUFFICIENCY   |
|   -----------------------------------------------------------------------   |
|   LOCATION              Distal tips of toes, heels,  Medial malleolus, gaiter|
|                         lateral malleolus, metatarsal area (lower medial leg)|
|   APPEARANCE            "Punched out", round, smooth  Shallow, irregular     |
|                         edges, pale/necrotic base    margins, ruddy red base|
|   EXUDATE               Minimal to dry               Copious, heavy exudate |
|   PAIN                  Severe; worsened by leg      Dull ache / heaviness; |
|                         elevation; relieved by       improved by elevation  |
|                         dependent dangling           and compression        |
|   PULSES                Diminished or ABSENT         NORMAL (may be hidden  |
|                                                      by edema)              |
|   SKIN FINDINGS         Pale on elevation, dependent Hyperpigmentation      |
|                         rubor; cool, shiny, hairless (hemosiderin), stasis  |
|                         skin, thickened nails        dermatitis, lipodermato-|
|                                                      sclerosis, warm skin   |
|   TREATMENT FOCUS       Revascularization; NO        GRADUATED COMPRESSION  |
|                         compression!                 (20-30 mmHg); Elevation|
+-----------------------------------------------------------------------------+

[!CAUTION] Compression Contraindication in Combined Disease: Never apply high-grade graduated compression stockings (30–40 mmHg) or Unna boots to a patient with chronic venous stasis ulcers without first verifying arterial competence via Ankle-Brachial Index (ABI). Applying compression therapy when underlying arterial disease is present ($\text{ABI} < 0.60–0.70$) occludes residual arterial inflow and precipitates acute ischemic limb gangrene.